Welcome to LookChem.com Sign In|Join Free
  • or
Entecavir is a cyclopentyl guanosine analog, a synthetic analogue of 2'-deoxyguanosine, and a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. It is a white to off-white/yellow crystalline powder, launched for the once-daily oral treatment of chronic hepatitis B virus (HBV) infection. Entecavir is the third nucleoside or nucleotide analog to be marketed for this indication, following lamivudine and adefovir dipivoxil. It is specifically indicated for HBV, whereas lamivudine is indicated for both HBV and HIV infections.

142217-69-4

Post Buying Request

142217-69-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

142217-69-4 Usage

Uses

Used in Pharmaceutical Industry:
Entecavir is used as an antiviral medication for the treatment of chronic hepatitis B virus (HBV) infection. It is particularly effective for adult patients with viral replication activity and serum transaminase levels that continue to increase, or for those with liver tissue showing pathological activity of chronic hepatitis B. Entecavir is currently considered the fastest and most potent nucleoside analog for reducing viral load, with the lowest mutation rate.
Entecavir is used as a nucleoside reverse transcriptase inhibitor, which is phosphorylated intracellularly to the active triphosphate form. This active form competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity. Although it has no activity against HIV, it is effective for the treatment of chronic hepatitis B.

Originator

BMS (US)

Mechanism of action

Entecavir is a nucleoside analog, or more specifically, a deoxyguanosine analogue that belongs to a class of carbocyclic nucleosides and inhibits reverse transcription, DNA replication and transcription in the viral replication process.

Pharmacokinetics

Entecavir had a mean terminal half-life ranging from 128 to 149 hours and an effective half-life of approximately 24 hours. Elimination was predominantly through renal excretion, with mean urinary recovery ranging from 62% to 73%.

Clinical Use

Treatment of chronic hepatitis B virus infection in patients >16 years of age.Entecavir comes as a tablet and solution (liquid) to take by mouth. It is usually taken once a day on an empty stomach, at least 2 hours after a meal and at least 2 hours before the next meal. Take entecavir at around the same time every day.

Side effects

The most common side effects of entecavir: the increase of ALT, fatigue, dizziness, nausea, abdominal pain, abdominal discomfort, abdominal discomfort, liver, muscle, insomnia, rubella and indigestion, also be found in neutrophils decreased slightly. These adverse reactions were mild to moderate. It also found that, as the same type of antiviral drugs, entecavir and the first generation of antiviral drugs have similar side effects, such as acid poisoning, hepatomegaly, liver fatty degeneration in the withdrawal will appear rebound phenomenon.

Synthesis

Entecavir is synthesized from 4-trimethylsilyl-3-butyn-2-one and acrolein. The key features of its preparation are: (1) a stereoselective boron–aldol reaction to afford the acyclic carbon skeleton of the methylenecylopentane moiety; (2) its cyclization by a Cp2TiCl-catalyzed intramolecular radical addition of an epoxide to an alkyne; and (3) the coupling with a purine derivative by a Mitsunobu reaction.

Check Digit Verification of cas no

The CAS Registry Mumber 142217-69-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,2,2,1 and 7 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 142217-69:
(8*1)+(7*4)+(6*2)+(5*2)+(4*1)+(3*7)+(2*6)+(1*9)=104
104 % 10 = 4
So 142217-69-4 is a valid CAS Registry Number.
InChI:InChI=1/C12H15N5O3/c1-5-6(3-18)8(19)2-7(5)17-4-14-9-10(17)15-12(13)16-11(9)20/h4,6-8,18-19H,1-3H2,(H3,13,15,16,20)/t6-,7-,8+/m0/s1

142217-69-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name Entecavir

1.2 Other means of identification

Product number -
Other names 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:142217-69-4 SDS

142217-69-4Synthetic route

((1 R,3S,5S)-5-acetoxy-3-(2-amino-6-chloro-9H-purin-9-yl)-2-methylenecyclopentyl)methyl acetate
1383812-22-3

((1 R,3S,5S)-5-acetoxy-3-(2-amino-6-chloro-9H-purin-9-yl)-2-methylenecyclopentyl)methyl acetate

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Stage #1: ((1 R,3S,5S)-5-acetoxy-3-(2-amino-6-chloro-9H-purin-9-yl)-2-methylenecyclopentyl)methyl acetate With sodium hydroxide at 80℃; for 2h;
Stage #2: With hydrogenchloride In water at 0℃; pH=7;
60%
(1S,3R)-3-(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-yn-1-ol
1383811-98-0

(1S,3R)-3-(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-yn-1-ol

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: chloro-trimethyl-silane; 2,4,6-trimethyl-pyridine; zinc / bis(cyclopentadienyl)titanium dichloride / tetrahydrofuran / 1 h / 20 °C / Inert atmosphere
2.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
3.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
4.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
5.1: sodium hydroxide / 2 h / 80 °C
5.2: 0 °C / pH 7
View Scheme
Multi-step reaction with 6 steps
1.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
2.1: manganese; 2,4,6-collidine hydrochloride / bis(cyclopentadienyl)titanium dichloride / tetrahydrofuran / 4 h / 20 °C
3.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
4.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
5.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
6.1: sodium hydroxide / 2 h / 80 °C
6.2: 0 °C / pH 7
View Scheme
Multi-step reaction with 7 steps
1.1: triethylamine; dmap / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
2.1: 2,4,6-trimethyl-pyridine; zinc; bis(cyclopentadienyl)titanium dichloride; chloro-trimethyl-silane / tetrahydrofuran / 4 h / 20 °C / Inert atmosphere
3.1: triethylamine; dmap / dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere
4.1: [(1S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid; methanol / 4 h / 0 - 20 °C / Inert atmosphere; Enzymatic reaction
5.1: triphenylphosphine / tetrahydrofuran / 0.25 h / 20 °C / Inert atmosphere
5.2: 4.17 h / -10 °C / Inert atmosphere
6.1: formic acid / 9 h / 50 °C / Inert atmosphere
7.1: sodium methylate / methanol / 0.5 h / 20 °C / Inert atmosphere
7.2: pH 7 / Inert atmosphere
View Scheme
(3S,5R)-7-(trimethylsilyl)hept-1-en-6-yne-3,5-diol
1383811-86-6

(3S,5R)-7-(trimethylsilyl)hept-1-en-6-yne-3,5-diol

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1.1: 1H-imidazole / tetrahydrofuran / 0 - 15 °C / Inert atmosphere
2.1: potassium carbonate; methanol / 1 h / 20 °C / Inert atmosphere
3.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 20 °C / Inert atmosphere
4.1: chloro-trimethyl-silane; 2,4,6-trimethyl-pyridine; zinc / bis(cyclopentadienyl)titanium dichloride / tetrahydrofuran / 1 h / 20 °C / Inert atmosphere
5.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
6.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
7.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
8.1: sodium hydroxide / 2 h / 80 °C
8.2: 0 °C / pH 7
View Scheme
Multi-step reaction with 8 steps
1.1: 1H-imidazole / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
2.1: potassium carbonate; methanol / 1 h / 20 °C / Inert atmosphere
3.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 20 °C / Inert atmosphere
4.1: chloro-trimethyl-silane; 2,4,6-trimethyl-pyridine; zinc / bis(cyclopentadienyl)titanium dichloride / tetrahydrofuran / 1 h / 20 °C / Inert atmosphere
5.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
6.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
7.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
8.1: sodium hydroxide / 2 h / 80 °C
8.2: 0 °C / pH 7
View Scheme
Multi-step reaction with 9 steps
1.1: 1H-imidazole / tetrahydrofuran / 0 - 15 °C / Inert atmosphere
2.1: potassium carbonate; methanol / 1 h / 20 °C / Inert atmosphere
3.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 20 °C / Inert atmosphere
4.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
5.1: manganese; 2,4,6-collidine hydrochloride / bis(cyclopentadienyl)titanium dichloride / tetrahydrofuran / 4 h / 20 °C
6.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
7.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
8.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
9.1: sodium hydroxide / 2 h / 80 °C
9.2: 0 °C / pH 7
View Scheme
Multi-step reaction with 9 steps
1.1: 1H-imidazole / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
2.1: potassium carbonate; methanol / 1 h / 20 °C / Inert atmosphere
3.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 20 °C / Inert atmosphere
4.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
5.1: manganese; 2,4,6-collidine hydrochloride / bis(cyclopentadienyl)titanium dichloride / tetrahydrofuran / 4 h / 20 °C
6.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
7.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
8.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
9.1: sodium hydroxide / 2 h / 80 °C
9.2: 0 °C / pH 7
View Scheme
Multi-step reaction with 10 steps
1.1: 1H-imidazole / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
2.1: potassium carbonate; methanol / 1 h / 20 °C / Inert atmosphere
3.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 20 °C / Inert atmosphere
4.1: triethylamine; dmap / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
5.1: 2,4,6-trimethyl-pyridine; zinc; bis(cyclopentadienyl)titanium dichloride; chloro-trimethyl-silane / tetrahydrofuran / 4 h / 20 °C / Inert atmosphere
6.1: triethylamine; dmap / dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere
7.1: [(1S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid; methanol / 4 h / 0 - 20 °C / Inert atmosphere; Enzymatic reaction
8.1: triphenylphosphine / tetrahydrofuran / 0.25 h / 20 °C / Inert atmosphere
8.2: 4.17 h / -10 °C / Inert atmosphere
9.1: formic acid / 9 h / 50 °C / Inert atmosphere
10.1: sodium methylate / methanol / 0.5 h / 20 °C / Inert atmosphere
10.2: pH 7 / Inert atmosphere
View Scheme
(3S,5R)-5-(tert-butyldimethylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yn-3-ol
1383811-90-2

(3S,5R)-5-(tert-butyldimethylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yn-3-ol

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1.1: potassium carbonate; methanol / 1 h / 20 °C / Inert atmosphere
2.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 20 °C / Inert atmosphere
3.1: chloro-trimethyl-silane; 2,4,6-trimethyl-pyridine; zinc / bis(cyclopentadienyl)titanium dichloride / tetrahydrofuran / 1 h / 20 °C / Inert atmosphere
4.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
5.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
6.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
7.1: sodium hydroxide / 2 h / 80 °C
7.2: 0 °C / pH 7
View Scheme
Multi-step reaction with 8 steps
1.1: potassium carbonate; methanol / 1 h / 20 °C / Inert atmosphere
2.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 20 °C / Inert atmosphere
3.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
4.1: manganese; 2,4,6-collidine hydrochloride / bis(cyclopentadienyl)titanium dichloride / tetrahydrofuran / 4 h / 20 °C
5.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
6.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
7.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
8.1: sodium hydroxide / 2 h / 80 °C
8.2: 0 °C / pH 7
View Scheme
Multi-step reaction with 9 steps
1.1: potassium carbonate; methanol / 1 h / 20 °C / Inert atmosphere
2.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 20 °C / Inert atmosphere
3.1: triethylamine; dmap / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
4.1: 2,4,6-trimethyl-pyridine; zinc; bis(cyclopentadienyl)titanium dichloride; chloro-trimethyl-silane / tetrahydrofuran / 4 h / 20 °C / Inert atmosphere
5.1: triethylamine; dmap / dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere
6.1: [(1S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid; methanol / 4 h / 0 - 20 °C / Inert atmosphere; Enzymatic reaction
7.1: triphenylphosphine / tetrahydrofuran / 0.25 h / 20 °C / Inert atmosphere
7.2: 4.17 h / -10 °C / Inert atmosphere
8.1: formic acid / 9 h / 50 °C / Inert atmosphere
9.1: sodium methylate / methanol / 0.5 h / 20 °C / Inert atmosphere
9.2: pH 7 / Inert atmosphere
View Scheme
(3S,5R)-5-(tert-butyldimethylsilyloxy)hept-1-en-6-yn-3-ol
1383811-94-6

(3S,5R)-5-(tert-butyldimethylsilyloxy)hept-1-en-6-yn-3-ol

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 20 °C / Inert atmosphere
2.1: chloro-trimethyl-silane; 2,4,6-trimethyl-pyridine; zinc / bis(cyclopentadienyl)titanium dichloride / tetrahydrofuran / 1 h / 20 °C / Inert atmosphere
3.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
4.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
5.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
6.1: sodium hydroxide / 2 h / 80 °C
6.2: 0 °C / pH 7
View Scheme
Multi-step reaction with 7 steps
1.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 20 °C / Inert atmosphere
2.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
3.1: manganese; 2,4,6-collidine hydrochloride / bis(cyclopentadienyl)titanium dichloride / tetrahydrofuran / 4 h / 20 °C
4.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
5.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
6.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
7.1: sodium hydroxide / 2 h / 80 °C
7.2: 0 °C / pH 7
View Scheme
Multi-step reaction with 8 steps
1.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 20 °C / Inert atmosphere
2.1: triethylamine; dmap / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
3.1: 2,4,6-trimethyl-pyridine; zinc; bis(cyclopentadienyl)titanium dichloride; chloro-trimethyl-silane / tetrahydrofuran / 4 h / 20 °C / Inert atmosphere
4.1: triethylamine; dmap / dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere
5.1: [(1S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid; methanol / 4 h / 0 - 20 °C / Inert atmosphere; Enzymatic reaction
6.1: triphenylphosphine / tetrahydrofuran / 0.25 h / 20 °C / Inert atmosphere
6.2: 4.17 h / -10 °C / Inert atmosphere
7.1: formic acid / 9 h / 50 °C / Inert atmosphere
8.1: sodium methylate / methanol / 0.5 h / 20 °C / Inert atmosphere
8.2: pH 7 / Inert atmosphere
View Scheme
(1S,3R)-3-(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-ynyl acetate
1383812-02-9

(1S,3R)-3-(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-ynyl acetate

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: manganese; 2,4,6-collidine hydrochloride / bis(cyclopentadienyl)titanium dichloride / tetrahydrofuran / 4 h / 20 °C
2.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
3.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
4.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
5.1: sodium hydroxide / 2 h / 80 °C
5.2: 0 °C / pH 7
View Scheme
Multi-step reaction with 6 steps
1.1: 2,4,6-trimethyl-pyridine; zinc; bis(cyclopentadienyl)titanium dichloride; chloro-trimethyl-silane / tetrahydrofuran / 4 h / 20 °C / Inert atmosphere
2.1: triethylamine; dmap / dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere
3.1: [(1S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid; methanol / 4 h / 0 - 20 °C / Inert atmosphere; Enzymatic reaction
4.1: triphenylphosphine / tetrahydrofuran / 0.25 h / 20 °C / Inert atmosphere
4.2: 4.17 h / -10 °C / Inert atmosphere
5.1: formic acid / 9 h / 50 °C / Inert atmosphere
6.1: sodium methylate / methanol / 0.5 h / 20 °C / Inert atmosphere
6.2: pH 7 / Inert atmosphere
View Scheme
(1S,2R,4R)-4-(tert-butyldimethylsilyloxy)-2-(hydroxymethyl)-3-methylenecyclopentyl acetate
1383812-06-3

(1S,2R,4R)-4-(tert-butyldimethylsilyloxy)-2-(hydroxymethyl)-3-methylenecyclopentyl acetate

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
2.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
3.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
4.1: sodium hydroxide / 2 h / 80 °C
4.2: 0 °C / pH 7
View Scheme
Multi-step reaction with 5 steps
1.1: triethylamine; dmap / dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere
2.1: [(1S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid; methanol / 4 h / 0 - 20 °C / Inert atmosphere; Enzymatic reaction
3.1: triphenylphosphine / tetrahydrofuran / 0.25 h / 20 °C / Inert atmosphere
3.2: 4.17 h / -10 °C / Inert atmosphere
4.1: formic acid / 9 h / 50 °C / Inert atmosphere
5.1: sodium methylate / methanol / 0.5 h / 20 °C / Inert atmosphere
5.2: pH 7 / Inert atmosphere
View Scheme
(1S,2R,4R)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)-3-methylenecyclopentanol
701278-65-1

(1S,2R,4R)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)-3-methylenecyclopentanol

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: dmap; triethylamine / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
2.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
3.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
4.1: sodium hydroxide / 2 h / 80 °C
4.2: 0 °C / pH 7
View Scheme
((1R,3R,5S)-5-acetoxy-3-(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methyl acetate
1383812-10-9

((1R,3R,5S)-5-acetoxy-3-(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methyl acetate

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: pyridine; hydrogen fluoride / tetrahydrofuran / 2 h / 0 - 20 °C / Inert atmosphere
2.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
3.1: sodium hydroxide / 2 h / 80 °C
3.2: 0 °C / pH 7
View Scheme
((1R,3R,5S)-5-acetoxy-3-hydroxy-2-methylenecyclo-pentyl) methyl acetate

((1R,3R,5S)-5-acetoxy-3-hydroxy-2-methylenecyclo-pentyl) methyl acetate

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: triphenylphosphine; di-isopropyl azodicarboxylate / N,N-dimethyl-formamide; tetrahydrofuran / 1 h / -40 °C / Inert atmosphere
2.1: sodium hydroxide / 2 h / 80 °C
2.2: 0 °C / pH 7
View Scheme
((1R,3R,5S)-5-acetoxy-3-(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methyl 4-nitrobenzoate
1435752-36-5

((1R,3R,5S)-5-acetoxy-3-(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methyl 4-nitrobenzoate

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: [(1S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid; methanol / 4 h / 0 - 20 °C / Inert atmosphere; Enzymatic reaction
2.1: triphenylphosphine / tetrahydrofuran / 0.25 h / 20 °C / Inert atmosphere
2.2: 4.17 h / -10 °C / Inert atmosphere
3.1: formic acid / 9 h / 50 °C / Inert atmosphere
4.1: sodium methylate / methanol / 0.5 h / 20 °C / Inert atmosphere
4.2: pH 7 / Inert atmosphere
View Scheme
((1R,3R,5S)-5-acetoxy-3-hydroxy-2-methylenecyclopentyl)methyl 4-nitrobenzoate
1435752-42-3

((1R,3R,5S)-5-acetoxy-3-hydroxy-2-methylenecyclopentyl)methyl 4-nitrobenzoate

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: triphenylphosphine / tetrahydrofuran / 0.25 h / 20 °C / Inert atmosphere
1.2: 4.17 h / -10 °C / Inert atmosphere
2.1: formic acid / 9 h / 50 °C / Inert atmosphere
3.1: sodium methylate / methanol / 0.5 h / 20 °C / Inert atmosphere
3.2: pH 7 / Inert atmosphere
View Scheme
((1R,3S,5S)-5-acetoxy-3-(2-amino-6-chloro-9H-purin-9-yl)-2-methylenecyclopentyl)methyl 4-nitrobenzoate
1435752-48-9

((1R,3S,5S)-5-acetoxy-3-(2-amino-6-chloro-9H-purin-9-yl)-2-methylenecyclopentyl)methyl 4-nitrobenzoate

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: formic acid / 9 h / 50 °C / Inert atmosphere
2.1: sodium methylate / methanol / 0.5 h / 20 °C / Inert atmosphere
2.2: pH 7 / Inert atmosphere
View Scheme
2-Amino-6-chloropurin
10310-21-1

2-Amino-6-chloropurin

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: triphenylphosphine / tetrahydrofuran / 0.25 h / 20 °C / Inert atmosphere
1.2: 4.17 h / -10 °C / Inert atmosphere
2.1: formic acid / 9 h / 50 °C / Inert atmosphere
3.1: sodium methylate / methanol / 0.5 h / 20 °C / Inert atmosphere
3.2: pH 7 / Inert atmosphere
View Scheme
((1R,3S,5S)-5-acetoxy-3-(2-amino-6-oxo-1H-purin-9(6H)-yl)-2-methylenecyclopentyl)methyl 4-nitrobenzoate
1435752-55-8

((1R,3S,5S)-5-acetoxy-3-(2-amino-6-oxo-1H-purin-9(6H)-yl)-2-methylenecyclopentyl)methyl 4-nitrobenzoate

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Stage #1: ((1R,3S,5S)-5-acetoxy-3-(2-amino-6-oxo-1H-purin-9(6H)-yl)-2-methylenecyclopentyl)methyl 4-nitrobenzoate With sodium methylate In methanol at 20℃; for 0.5h; Inert atmosphere;
Stage #2: With hydrogenchloride; tert-butyl methyl ether In methanol pH=7; Inert atmosphere;
2.37 g
C10H20O2Si

C10H20O2Si

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 11 steps
1.1: sodium acetate; dihydrogen peroxide / tetrahydrofuran; water / 0.83 h / 0 - 20 °C / Inert atmosphere
1.2: Enzymatic reaction
2.1: 1H-imidazole / tetrahydrofuran / 5 h / 0 - 20 °C / Inert atmosphere
3.1: potassium carbonate; methanol / 1 h / 20 °C / Inert atmosphere
4.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 20 °C / Inert atmosphere
5.1: triethylamine; dmap / dichloromethane / 1 h / 0 - 20 °C / Inert atmosphere
6.1: 2,4,6-trimethyl-pyridine; zinc; bis(cyclopentadienyl)titanium dichloride; chloro-trimethyl-silane / tetrahydrofuran / 4 h / 20 °C / Inert atmosphere
7.1: triethylamine; dmap / dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere
8.1: [(1S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid; methanol / 4 h / 0 - 20 °C / Inert atmosphere; Enzymatic reaction
9.1: triphenylphosphine / tetrahydrofuran / 0.25 h / 20 °C / Inert atmosphere
9.2: 4.17 h / -10 °C / Inert atmosphere
10.1: formic acid / 9 h / 50 °C / Inert atmosphere
11.1: sodium methylate / methanol / 0.5 h / 20 °C / Inert atmosphere
11.2: pH 7 / Inert atmosphere
View Scheme
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

ω-chlorocaprylic acid
1795-62-6

ω-chlorocaprylic acid

N-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylene-cyclopentyl]-2-6H-purin-6-oneoctanamide

N-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylene-cyclopentyl]-2-6H-purin-6-oneoctanamide

Conditions
ConditionsYield
With pyridine In dichloromethane at 30℃; for 8h;74%
n-dodecanoyl chloride
112-16-3

n-dodecanoyl chloride

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

N-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylene-cyclopentyl]-2-6H-purin-6-onelaurylamide

N-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylene-cyclopentyl]-2-6H-purin-6-onelaurylamide

Conditions
ConditionsYield
With pyridine In dichloromethane at 50℃; for 8h;68%
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

Reaxys ID: 30033682

Reaxys ID: 30033682

Reaxys ID: 30033679

Reaxys ID: 30033679

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(((S)-1-isopropoxycarbonylethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(((S)-1-isopropoxycarbonylethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N,N-dimethyl-formamide / 20 °C
2: 1-methyl-1H-imidazole / tetrahydrofuran / 20 °C
View Scheme
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(((S)-1-cyclohexyloxycarbonylethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(((S)-1-cyclohexyloxycarbonylethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N,N-dimethyl-formamide / 20 °C
2: 1-methyl-1H-imidazole / tetrahydrofuran / 20 °C
View Scheme
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-((methoxycarbonylmethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-((methoxycarbonylmethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N,N-dimethyl-formamide / 20 °C
2: 1-methyl-1H-imidazole / tetrahydrofuran / 20 °C
View Scheme
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-((ethoxycarbonylmethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-((ethoxycarbonylmethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N,N-dimethyl-formamide / 20 °C
2: 1-methyl-1H-imidazole / tetrahydrofuran / 20 °C
View Scheme
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-((isopropoxycarbonylmethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-((isopropoxycarbonylmethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N,N-dimethyl-formamide / 20 °C
2: 1-methyl-1H-imidazole / tetrahydrofuran / 20 °C
View Scheme
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(((S)-1-ethoxycarbonylethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(((S)-1-ethoxycarbonylethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: N,N-dimethyl-formamide / 20 °C
2: 1-methyl-1H-imidazole / tetrahydrofuran / 20 °C
View Scheme
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

A

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(((R)-(1S)-1-ethoxycarbonylethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(((R)-(1S)-1-ethoxycarbonylethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

B

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(((S)-(1S)-1-ethoxycarbonylethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(((S)-(1S)-1-ethoxycarbonylethylamino(phenoxy)phosphoryl)oxymethyl)-2-methylidenecyclopentyl]-6H-purin-6-one

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: N,N-dimethyl-formamide / 20 °C
2: 1-methyl-1H-imidazole / tetrahydrofuran / 20 °C
3: Diacel's Chiralpak AS / acetonitrile; ethanol
View Scheme
Multi-step reaction with 3 steps
1: N,N-dimethyl-formamide / 20 °C
2: 1-methyl-1H-imidazole / tetrahydrofuran / 20 °C
3: Diacel's Chiralpak AS / acetonitrile; isopropyl alcohol
View Scheme
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one
142217-69-4

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one

N,N-dimethyl-formamide dimethyl acetal
4637-24-5

N,N-dimethyl-formamide dimethyl acetal

C15H20N6O3

C15H20N6O3

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 20℃;

142217-69-4Downstream Products

142217-69-4Relevant academic research and scientific papers

A novel and efficient synthesis of Entecavir

Liu, Xiaoyu,Jiao, Xiaozhen,Wu, Qian,Tian, Chengsen,Li, Renze,Xie, Ping

, p. 3805 - 3807 (2012)

A practical synthesis of Entecavir (1) has been accomplished in 10 steps with 21% overall yield. The key steps to construct the five-membered carbocyclic framework 2 are a ring-closing metathesis and a diethyl-aluminum 2,2,6,6-tetramethyl piperidide (DA-TMS) mediated epoxide isomerization. Furthermore, the guanine was introduced by modified Mitsunobu reaction.

Total Synthesis of Entecavir: A Robust Route for Pilot Production

Xu, Hua,Wang, Fang,Xue, Weicai,Zheng, Yunjie,Wang, Qi,Qiu, Fayang G.,Jin, Yehua

, p. 377 - 384 (2018)

A practical synthetic route for pilot production of entecavir is described. It is safe, robust, and scalable to kilogram scale. Starting from (S)-(+)-carvone, this synthetic route consists of a series of highly efficient reactions including a Favorskii rearrangement-elimination-epimerization sequence to establish the cyclopentene skeleton, the Baeyer-Villiger oxidation/rearrangement to afford the correct configuration of the secondary alcohol, and a directed homoallylic epoxidation followed by epoxide ring-opening to introduce the hydroxyl group suitable for the Mitsunobu reaction. In addition, the synthesis contains only four brief chromatographic purifications.

Novel preparation method and intermediates of entecavir

-

, (2021/04/10)

The invention provides novel intermediates used for entecavir synthesis, compounds shown as a formula II and a formula III in the description, and a novel method for synthesizing entecavir by using the novel intermediates. When the novel intermediates are used for synthesizing entecavir, not only can the synthesis yield be remarkably improved, but also the production cost can be reduced.

Improved entecavir intermediate synthesis process and improved entecavir synthesis process

-

, (2020/10/14)

The invention discloses an improved entecavir intermediate synthesis process and an improved entecavir synthesis process, and relates to the technical field of drug synthesis. The invention disclosesan improved entecavir intermediate synthesis process. In the synthesis process of an amino protection reaction product, amino protecting groups are added in batches; and the ratio of the reaction rawmaterials is optimized, so that the problems of long reaction time and relatively low amino protection reaction yield due to adoption of a one-time complete feeding mode in an existing synthesis modeare solved, the synthesis time of an amino protection reaction product is shortened to 50-70 minutes, and the obtained product is high in yield and purity. According to the improved entecavir synthesis process, in the amino protection reaction product synthesis process, reaction conditions are effectively optimized, and the purity of obtained entecavir reaches 99% or above.

Entecavir intermediate, synthetic method thereof and synthetic method of entecavir

-

, (2020/07/29)

The invention belongs to the technical field of organic synthesis, and provides an entecavir intermediate, a synthesis method thereof and a method for synthesizing entecavir by using the entecavir intermediate. The intermediate and the methods have the advantages of easily available raw materials, low price, shortest synthesis steps, mild reaction conditions, easiness in control, simple equipmentrequirements, high total yield of products and easiness in industrial production.

Entecavir intermediate and synthesis method thereof as well as method for synthesis of entecavir

-

Paragraph 0199; 0210-0211; 0216-0220, (2019/05/15)

The invention relates to an entecavir intermediate and a preparation method thereof and a method for synthesis of entecavir by using the intermediate. The methods for synthesis of the entecavir and the entecavir intermediate have the advantages of controllable chirality, high yield and high product purity, raw materials are wide in source, reagents are cheap and easily available, the reaction is simple, the operation is simple and convenient, green and environment-friendly effects are achieved, and the method is suitable for industrial large-scale production.

Method for synthesizing entecavir

-

Paragraph 0040; 0060-0062; 0069, (2019/04/27)

The invention provides a method for synthesizing entecavir. The method comprises the steps of carrying out condensation ring-closure reaction, bromination addition reaction, reduction reaction, Witting reaction and the like. The method has the beneficial effects that the reaction raw material is easy to obtain, the reaction process is simple in operation, the requirement on reaction equipment is low, the reaction condition is relatively mild and the yield and the content are high.

A new scalable synthesis of entecavir

Gioti, Efthymia G.,Koftis, Theocharis V.,Neokosmidis, Efstratios,Vastardi, Elli,Kotoulas, Stefanos S.,Trakossas, Sakellarios,Tsatsas, Theodoros,Anagnostaki, Elizabeth E.,Panagiotidis, Theodoros D.,Zacharis, Constantinos,Tolika, Evanthia P.,Varvogli, Anastasia-Aikaterini,Andreou, Thanos,Gallos, John K.

, p. 519 - 527 (2017/12/29)

A new synthesis of entecavir from D-glucose in an average total yield of 3.5% was achieved via an intramolecular nitrile oxide cycloaddition (INOC) reaction and a Peterson olefination as key-steps. The present process was designed for industrial application, using widely available raw materials, simple and cheap reagents and avoiding low reaction temperatures, which are very common in the synthetic approaches towards similarly complex structures.

Entecavir industrial preparation method (by machine translation)

-

, (2018/07/15)

The invention discloses entecavir industrial preparation method, which belongs to the technical field of organic synthesis. Including: Nysted reagent and intermediate VIII reaction, after the reaction is finished adding quenching fluid and holding the reaction system pH value of 7.0 - 8.5, obtained after the completion of reaction intermediates IX; intermediate IX react with hydrochloric acid, after the reaction is finished by adding the extractant and adjust pH value to 6.5 - 7.0, taking organic phase concentrated to 1/15 - 1/10 volume, crystallization, solid-liquid separation to obtain the intermediate X; intermediate with boron trichloride in dichloromethane in the X reaction, intermediate X with boron trichloride in a molar ratio of 1:5 - 10, the reaction temperature is - 30 — - 20 °C, after the reaction is finished cooling to - 30 °C following, dripping methanol, after the completion of the dropping the evaporation and once again by adding methanol, concentrated under reduced pressure, dryness and add into the water with the organic solvent of the extractant B, [...], adjust pH value to 6.5 - 7.0, concentrated, refine to get entecavir. (by machine translation)

SYNTHETIC METHOD OF ENTECAVIR AND INTERMEDIATE COMPOUNDS THEREOF

-

Page/Page column 87, (2017/10/31)

The present invention relates to preparation method of drugs and intermediate compounds thereof, in particular, to preparation method of entecavir, intermediate compounds thereof and synthetic method of said intermediate compounds.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 142217-69-4